Abstract

Abstract : Towards developing a new chemotherapy for African trypanosomiasis, nine strains of Trypanosoma brucei rhodesiense were acquired and used to establish mouse model of African trypanosomiasis which will be suitable for testing drug protocols against both early and late stage disease. Experiments were performed to determine the maximum tolerated difluoromethylornithine (DFMO) dose. DFMO was used to treat groups of mice infected with different strains of T. brucei rhodesiense at the early stage of infection. Variation was found in the sensitivity of the various strains to DFMO as predicted. A range of combinations of DFMO and suramin were administered to uninfected mice in order to detect any possible toxic interactions. Keywords: African Trypanosomiasis; Trypanosoma Brucei Rhodesiense; DFMO; Difluoromethylornithine; chemotherapy; Late Stage Disease.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.